Publications by authors named "M L Bringas"
Objectives: Our objective was to evaluate the impact of COVID-19 on the proportion of past-year HIV testing in Peru.
Methods: Utilizing data from the National Demographic and Health Survey of Peru from 2014 to 2022, we conducted an interrupted time series analysis. The proportion of past-year HIV testing per quarter of each year was considered our unit of analysis.
Article Synopsis
- Parkinson's disease affects dendritic spines in specific brain regions, impacting their shape and function, which is essential for understanding treatment options.
- This study examined the effects of 6-OHDA lesions in male rats on behavior and dendritic spine changes, testing the combined treatment of pramipexole and rasagiline.
- Despite the lesions leading to balance issues and decreased dendritic spine density in some neurons, the combined treatment did not improve symptoms but did modify the types of dendritic spines in certain brain areas, highlighting their potential as targets for new therapies.
Introduction: We aimed to determine if advanced BRAF-mutant NSCLC has a higher thromboembolic events (TEE) rate than the expected.
Methods: Between 2008 and 2021, 182 patients with BRAF-mutant advanced NSCLC (BRAF V600E, n = 70; BRAF non-V600E, n = 112) were retrospectively identified from 18 centers in Spain. Patients received chemotherapy (n = 147), immunotherapy (n = 69), targeted therapy (n = 42), and immunotherapy + chemotherapy (n = 26).
The prevalence of autism spectrum disorder (ASD), a neurodevelopmental condition that impacts social interaction and sensory processing, is rising. Valproic acid (VPA) exposure during pregnancy causes autistic-like traits in offspring. Olanzapine (OLZ), an atypical antipsychotic, is used to treat ASD.
View Article and Find Full Text PDFUnlabelled: Although many studies have explored the depletion of tumor-associated macrophages (TAM) as a therapeutic strategy for solid tumors, currently available compounds suffer from poor efficacy and dose-limiting side effects. Here, we developed a novel TAM-depleting agent ("OximUNO") that specifically targets CD206 TAMs and demonstrated efficacy in a triple-negative breast cancer (TNBC) mouse model. OximUNO comprises a star-shaped polyglutamate (St-PGA) decorated with the CD206-targeting peptide mUNO that carries the chemotherapeutic drug doxorubicin (DOX).
View Article and Find Full Text PDF